세계의 바이오베터 시장 - 예측(2025-2030년)

The Biobetters Market is anticipated to expand from USD 66.603 billion in 2025 to USD 97.907 billion in 2030, registering an 8.01% CAGR.

The biobetters market is poised for modest growth, driven by their lower development costs compared to originator biologics and their strategic importance amid rising biosimilar competition. Biobetters are enhanced versions of existing biologics, designed to target the same biological pathways but with improvements in efficacy, safety, or administration. These enhancements, achieved through chemical modifications, protein fusion, altered amino acid sequences, or optimized glycosylation patterns, result in longer-lasting effects, lower dosing requirements, and reduced side effects. Unlike biosimilars, which aim for clinical equivalence to reference products, biobetters are distinct new molecular entities (NMEs) subject to rigorous regulatory standards akin to novel drugs. In the United States and other regions, they are evaluated under frameworks for innovator molecules, ensuring robust safety and efficacy validation.

This research study examines current market trends, focusing on demand, supply, and sales dynamics, alongside recent developments in the biobetters sector. Key drivers include major manufacturers' investments in biobetters to differentiate from biosimilars, leveraging established clinical pathways to streamline development and improve approval odds. The expiration of patents for blockbuster biologics creates opportunities for companies to develop biobetters, offering patent-protected NMEs with enhanced profiles. However, a significant restraint is the lack of awareness among patients regarding biobetters, which may hinder adoption and market penetration in certain regions.

The study segments the global biobetters market by type and geography. By type, the market includes monoclonal antibodies, vaccines, recombinant proteins, and others, with monoclonal antibodies expected to dominate due to favorable regulatory policies and high adoption rates in emerging economies. Their therapeutic versatility and established clinical success drive their prominence. Geographically, the market is divided into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. Europe is anticipated to hold a significant share, attributed to well-defined regulatory approval guidelines and extensive research activities focused on biobetter development. These factors foster innovation and market growth in the region.

The analysis provides in-depth insights into market evolution, highlighting trends such as the integration of advanced delivery systems and the focus on patient-centric formulations. Regulatory frameworks are thoroughly examined, offering stakeholders clarity on compliance requirements, including clinical trial mandates and intellectual property considerations. These frameworks shape market strategies, particularly in regions with stringent standards like Europe.

Competitive intelligence, derived from secondary research, underscores the strategic moves of key players investing in biobetters to maintain market leadership. The study employs both bottom-up and top-down approaches to estimate market size, aggregating data from product segments and validating it through primary inputs from stakeholders across the biobetters value chain. Data triangulation ensures accurate market breakdowns and reliable forecasts, presented through analytical narratives, charts, and graphics for efficient comprehension.

For industry experts, this study highlights the interplay of innovation, regulation, and competition in driving the biobetters market. Stakeholders can leverage these insights for strategic planning, investment prioritization, and market positioning, capitalizing on the opportunities presented by patent expirations and the demand for enhanced biologics. Despite challenges like patient awareness, the biobetters market offers a compelling growth trajectory for companies navigating the evolving biopharmaceutical landscape.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

By Type

• Monoclonal Antibodies (mAbs)
• Vaccines
• Recombinant Proteins
• Antibody-Drug Conjugates (ADCs)
• Others

By Application

• Oncology
• Neurology
• Nephrology
• Autoimmune & Inflammatory Diseases
• Infectious Diseases
• Others

By End-User

• Biopharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL BIOBETTERS MARKET BY TYPE

• 5.1. Introduction
• 5.2. Monoclonal Antibodies (mAbs)
• 5.3. Vaccines
• 5.4. Recombinant Proteins
• 5.5. Antibody-Drug Conjugates (ADCs)
• 5.6. Others

6. GLOBAL BIOBETTERS MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Oncology
• 6.3. Neurology
• 6.4. Nephrology
• 6.5. Autoimmune & Inflammatory Diseases
• 6.6. Infectious Diseases
• 6.7. Others

7. GLOBAL BIOBETTERS MARKET BY END-USER

• 7.1. Introduction
• 7.2. Biopharmaceutical Companies
• 7.3. Contract Research Organizations (CROs)
• 7.4. Academic & Research Institutes

8. GLOBAL BIOBETTERS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End-User
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Type
  • 8.3.2. By Application
  • 8.3.3. By End-User
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Type
  • 8.4.2. By Application
  • 8.4.3. By End-User
  • 8.4.4. By Country
    • 8.4.4.1. United Kingdom
    • 8.4.4.2. Germany
    • 8.4.4.3. France
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Type
  • 8.5.2. By Application
  • 8.5.3. By End-User
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Others
• 8.6. Asia Pacific
  • 8.6.1. By Type
  • 8.6.2. By Application
  • 8.6.3. By End-User
  • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. Japan
    • 8.6.4.3. India
    • 8.6.4.4. South Korea
    • 8.6.4.5. Taiwan
    • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Celltrion
• 10.2. GC Pharma
• 10.3. Ildong Pharmaceutical Co., Ltd.
• 10.4. Samsung Bioepis
• 10.5. Amgen Inc.
• 10.6. Novartis AG
• 10.7. Galil-Ofek

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key benefits for the stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations